Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APL 1202

Drug Profile

APL 1202

Alternative Names: APL-1202

Latest Information Update: 24 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University
  • Developer Asieris Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Bladder cancer
  • Phase I Prostate cancer

Most Recent Events

  • 21 Jun 2019 Asieris completes enrollment in a phase Ib trial cancer (Combination therapy, Monotherapy) in USA (PO) (NCT03672240)
  • 01 Nov 2018 The US FDA approves IND application for APL 1202 in bladder cancer before November 2018
  • 01 Oct 2018 Phase-I/II clinical trials in Bladder cancer (Combination therapy, Monotherapy) in USA (PO) (NCT03672240)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top